DE60026285D1 - Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst - Google Patents
Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasstInfo
- Publication number
- DE60026285D1 DE60026285D1 DE60026285T DE60026285T DE60026285D1 DE 60026285 D1 DE60026285 D1 DE 60026285D1 DE 60026285 T DE60026285 T DE 60026285T DE 60026285 T DE60026285 T DE 60026285T DE 60026285 D1 DE60026285 D1 DE 60026285D1
- Authority
- DE
- Germany
- Prior art keywords
- pepsinogen
- pgi
- vitamin
- concentrations
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI990991 | 1999-04-30 | ||
FI990991A FI990991A (fi) | 1999-04-30 | 1999-04-30 | Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi |
PCT/FI2000/000376 WO2000067029A1 (en) | 1999-04-30 | 2000-04-28 | Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60026285D1 true DE60026285D1 (de) | 2006-04-27 |
DE60026285T2 DE60026285T2 (de) | 2006-11-09 |
Family
ID=8554566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60026285T Expired - Lifetime DE60026285T2 (de) | 1999-04-30 | 2000-04-28 | Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1173764B1 (de) |
JP (1) | JP2002543430A (de) |
CN (1) | CN1353816A (de) |
AT (1) | ATE319088T1 (de) |
AU (1) | AU4299700A (de) |
DE (1) | DE60026285T2 (de) |
DK (1) | DK1173764T3 (de) |
ES (1) | ES2258453T3 (de) |
FI (1) | FI990991A (de) |
PT (1) | PT1173764E (de) |
RU (1) | RU2224258C2 (de) |
WO (1) | WO2000067029A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
FI20065542A0 (fi) * | 2006-09-01 | 2006-09-01 | Biohit Oyj | Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
-
1999
- 1999-04-30 FI FI990991A patent/FI990991A/fi unknown
-
2000
- 2000-04-28 DK DK00922683T patent/DK1173764T3/da active
- 2000-04-28 DE DE60026285T patent/DE60026285T2/de not_active Expired - Lifetime
- 2000-04-28 EP EP00922683A patent/EP1173764B1/de not_active Expired - Lifetime
- 2000-04-28 AT AT00922683T patent/ATE319088T1/de not_active IP Right Cessation
- 2000-04-28 CN CN00808519A patent/CN1353816A/zh active Pending
- 2000-04-28 RU RU2001132334/15A patent/RU2224258C2/ru active
- 2000-04-28 JP JP2000615816A patent/JP2002543430A/ja active Pending
- 2000-04-28 ES ES00922683T patent/ES2258453T3/es not_active Expired - Lifetime
- 2000-04-28 PT PT00922683T patent/PT1173764E/pt unknown
- 2000-04-28 AU AU42997/00A patent/AU4299700A/en not_active Abandoned
- 2000-04-28 WO PCT/FI2000/000376 patent/WO2000067029A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1173764A1 (de) | 2002-01-23 |
ATE319088T1 (de) | 2006-03-15 |
PT1173764E (pt) | 2006-06-30 |
FI990991A (fi) | 2000-10-31 |
FI990991A0 (fi) | 1999-04-30 |
CN1353816A (zh) | 2002-06-12 |
DE60026285T2 (de) | 2006-11-09 |
WO2000067029A1 (en) | 2000-11-09 |
ES2258453T3 (es) | 2006-09-01 |
RU2224258C2 (ru) | 2004-02-20 |
DK1173764T3 (da) | 2006-05-08 |
AU4299700A (en) | 2000-11-17 |
EP1173764B1 (de) | 2006-03-01 |
JP2002543430A (ja) | 2002-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003056314A3 (de) | Analysensystem zur bestimmung einer analytkonzentration unter berücksichtigung von proben- und analytunabhängigen lichtintensitätsänderungen | |
ATE378404T1 (de) | Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon | |
DE69904956D1 (de) | Testsatz und verfahren zur qualitätsprüfung von einem iontophoretischen probenahmesystem | |
DE69837015D1 (de) | Verfahren zur Stabilisierung und Messung von Troponinkomplexen | |
WO2001075450A3 (en) | Fluorescent lifetime assays for non-invasive quantification of analytes | |
ATE232559T1 (de) | Verfahren zur signalverstärkung | |
WO2003043487A3 (en) | Method of using a non-antibody protein to detect and measure an analyte | |
ATE278805T1 (de) | Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien | |
DE60239968D1 (de) | Sche | |
WO2004011607A3 (en) | Reagent and method for determination of a substance using an immunoaggregator | |
DE60021369D1 (de) | Verfahren zur abschätzung eines magengeschwür-risikos | |
EP1221620A3 (de) | Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit | |
DE60315715D1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
ATE333091T1 (de) | Verfahren zur messung von blutersatzstoffen | |
ATE467831T1 (de) | Verfahren und vorrichtung zum nachweis flüchtiger analyten in luftproben | |
DE60310012D1 (de) | Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer | |
ATE333510T1 (de) | Enzymatische messung von mycophenolsäure | |
CA2586654A1 (en) | Use of asc as a marker for colorectal cancer | |
ATE437372T1 (de) | Verfahren zur messung von proinsulin und c-peptid sowie kit dafür | |
DE60026285D1 (de) | Verfahren zur abschätzung des individuellen risikos einer irreversiblen nervenschädigung, das schritte zur quantitativen bestimmung der pepsinogen-i (pgi) und vitamin b12 konzentrationen umfasst | |
NO903748D0 (no) | Fremgangsmaate ved enzymatisk bestemmelse av analyttkonsentrasjoner. | |
PT1190245E (pt) | Deteccao de alergenos | |
RU2001132334A (ru) | Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 | |
ATE274702T1 (de) | Verwendung derivatisierter reagenzien in chemilumineszenz- und elektrochemilumineszenz- nachweisverfahren | |
RU2002107982A (ru) | Способ идентификации индивидуума с риском сосудистого и ракового заболевания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: BIOHIT OYJ, HELSINKI, FI |
|
8364 | No opposition during term of opposition |